康方生物(09926.HK) 公布,公司自主研发的全球首创PD-1/VEGF双特异性肿瘤免疫治疗药物依沃西单抗注射液,其国际市场开发合作伙伴Summit Therapeutics(SMMT.US) 已与美国辉瑞(PFE.US) 达成临床试验合作,将共同推进依沃西与辉瑞多款抗体偶联(ADCs)药物在多种实体瘤中的联合治疗应用。根据协议条款,辉瑞将全面负责本次合作的系列临床试验的开展,Summit...
Source Link康方生物(09926.HK) 公布,公司自主研发的全球首创PD-1/VEGF双特异性肿瘤免疫治疗药物依沃西单抗注射液,其国际市场开发合作伙伴Summit Therapeutics(SMMT.US) 已与美国辉瑞(PFE.US) 达成临床试验合作,将共同推进依沃西与辉瑞多款抗体偶联(ADCs)药物在多种实体瘤中的联合治疗应用。根据协议条款,辉瑞将全面负责本次合作的系列临床试验的开展,Summit...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.